clinical trial · NCT04705831
Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection
IMMUNOe Research Centers·phase2·completed·n = 40
Post-Viral Fatigue SyndromePost-Viral Disorder (Disorder)Covid19Ruconest
brief summary
Randomized, Double Blind, Placebo Controlled, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection.
started
Jan 11, 2021
primary completion
Mar 30, 2024
completion
Jul 1, 2024
last updated
Aug 11, 2025
detailed description
This study will last approximately 19 weeks including 16 infusions total, each one week apart. This is to help patients that have developed "Post-Viral Fatigue Syndrome" which can include symptoms such as: extreme fatigue, lost of taste, brain fog, and/or seizures.
official title
A Randomized, Double Blind, Placebo Controlled, Cross-Over, Proof-of-Concept Study to Evaluate the Benefit of RUCONEST (C1 Esterase Inhibitor [Recombinant]) in Improving Neurological Symptoms in Post-SARS-CoV-2 Infection
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol